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A b s t r a c t
The publication of the first non-randomised proof-of-concept trial of renal denervation as a treatment modality in treatment- 
-resistant hypertension set the stage for a search for novel devices with the expectation that technology would reduce the 
burden of hypertension by reducing or eliminating the costly and lifelong use of blood pressure-lowering medications. As we 
demonstrate in this review, this idea was so attractive to manufacturers and invasive cardiologists and radiologists that they 
overlooked decades of careful pathophysiological research in a disease that remains enigmatic but is still a major cause of cardio-
vascular mortality worldwide. To make our point, we first reviewed the prevalence and risks associated with treatment-resistant 
hypertension. Next, we highlighted the key points required for the diagnosis of treatment-resistant hypertension, including the 
recording of ambulatory blood pressure and the assessment of adherence to medication. Finally, we summarised new insights 
in the management of treatment-resistant hypertension by medication and devices as well as in future research. Throughout 
our review, we focused on new evidence that had become available since 2013. Our conclusion is that optimising medical 
treatment based on simple algorithms remains the state of the art in treatment-resistant hypertension. 
Key words: resistant hypertension, pharmacology, sympathetic nervous system, baroreflex, renal denervation
Kardiol Pol 2018; 76, 7: 1031–1042
INTRODUCTION
Hypertension remains the predominant driver of cardiovas-
cular disease, which is the leading cause of morbidity and 
mortality worldwide [1]. Resistant hypertension is a seated 
office blood pressure (BP) of at least 140 mmHg systolic or 
90 mmHg diastolic in patients on a maximally tolerated dose 
of three or more antihypertensive agents, one of which must 
be a diuretic [2, 3]. In addition, some guidelines recommend 
that the daytime ambulatory BP should be at least 135 mmHg 
systolic or 85 mmHg diastolic on the same regimen [2–4] to 
exclude white-coat hypertension. Thus, true resistant hyper-
tension refers to a diagnosis of essential hypertension with 
exclusion of all other potential causes of uncontrolled BP, 
including secondary hypertension, pseudo-resistance due to 
poor adherence, or the white-coat effect [2, 3]. 
Resistant hypertension is more likely to occur in patients 
with increased sympathetic drive, such as obesity, diabetes, 
or renal dysfunction [5–8]. Resistant hypertensive patients 
are at high risk of cardiovascular complications [9, 10]. Until 
recently, treatment options included lifestyle interventions, 
intensified pharmacological treatment, renal denervation, and 
stimulation of carotid sinus. In our review, we will highlight 
the progress made from the state of the art in 2013 [3]. We 
will focus on recent studies on the prevalence, risk, diagnosis, 
and management of resistant hypertension, limitations of the 
current evidence, and propose directions for future research. 
EPIDEMIOLOGY 
Most epidemiological studies lack key components for ascer-
taining the presence of resistant hypertension, such as medica-
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tion adherence and ambulatory BP measurement. The ideal 
design to estimate the prevalence of true resistant hyperten-
sion would be a large prospective cohort study of hypertensive 
patients with BP control ascertained by ambulatory monitoring 
after forced titration up to full doses of three different classes 
of hypertensive medications, including a diuretic. However, 
such a prospective study has not yet been published. Recently, 
the prevalence of resistant hypertension is estimated mainly 
from observational studies and outcome-based clinical trials. 
Prevalence 
The prevalence of hypertension in previous studies is highly 
variable, ranging from 9% to 18%, due to divergent diagnos-
tic approaches and the non-exclusion of pseudo-resistant 
hypertension. In a meta-analysis of 961,035 individuals, the 
prevalence of resistant hypertension was 13.7% (95% con-
fidence interval [CI] 11.2–16.2) in 20 observational studies 
and 16.3% (95% CI 10.7–21.9) in four randomised clinical 
trials, but pseudo-resistance caused by suboptimal drug dos-
ing, poor medication adherence, and the white-coat effect 
could not be ruled out [11]. Of 68,045 patients enrolled in 
the Spanish Ambulatory Blood Pressure Monitoring Registry, 
8295 (12.2%) had resistant hypertension based on having an 
increased office BP while on treatment with three or more 
antihypertensive drugs, including a diuretic, but the preva-
lence decreased to 5184 (7.6%) after white-coat hyperten-
sion had been excluded [12]. In the MINISAL-SIIA survey, 
representative for 47 Italian centres, investigators excluded 
secondary and white-coat hypertension. The prevalence of 
resistant hypertension among patients on stable drug therapy 
was 8.2% and increased 1.5-fold per one standard deviation 
increase in age and body mass index. However, accounting 
for an appropriate lifestyle, as exemplified by a 24-h urinary 
sodium excretion below 100 mmol and a normal body mass 
index, reduced the prevalence to 0.8% [13]. 
Associated risks 
In a retrospective analysis of two integrated health care 
plans in the United States, the incidence of resistant hyper-
tension among 24,499 patients was 1.9% within 1.5 years 
(median) from initial treatment with a rate of 0.7 cases per 
100 patient-years of follow-up [10]. Patients with resistant 
hypertension had higher rates of baseline diabetes (17.7% 
vs. 9.6%) compared to those with non-resistant hypertension. 
In multivariable-adjusted analyses, the hazard ratio (HR) for 
incidental adverse cardiovascular outcomes over 3.8 years 
(median) associated with resistant hypertension was 1.47 (95% 
CI 1.33–1.62) [10]. Four recent studies strengthened the evi-
dence associating resistant hypertension with adverse health 
outcomes [7, 14–16], but only one [7] applied ambulatory BP 
monitoring to exclude pseudo-resistance and none assessed 
treatment adherence. Among 14,684 patients randomised 
in the Antihypertensive and Lipid-Lowering to Prevent Heart 
Attack Trial (ALLHAT) [15], the multivariable-adjusted HRs as-
sociated with apparent resistant hypertension vs. non-resistant 
hypertension were 1.30 (95% CI 1.11–1.52) for all-cause 
mortality, 1.44 (95% CI 1.18–1.76) for coronary heart dis-
ease, 1.88 (95% CI 1.52–2.34) for heart failure, 1.57 (95% 
CI 1.18–2.08) for stroke, and 1.95 (95% CI 1.11–3.41) for 
end-stage renal disease. Among 470,386 individuals enrolled 
in the Kaiser Permanente Southern California health care 
programme [16], these HRs, respectively, were 1.06 (95% 
CI 1.03–1.08), 1.24 (95% CI 1.20–1.28), 1.46 (95% CI 
1.40–1.52), 1.14 (95% CI 1.10–1.19), and 1.32 (95% CI 
1.27–1.37). Among 1911 treated hypertensive patients, the 
HR of all cardiovascular events contrasting patients with per-
sistent hypertension vs. never having resistant hypertension 
was 2.22 (95% CI 1.21–4.05) [14]. In a study of 436 patients 
with chronic kidney disease and a diagnosis of office hyper-
tension [7], the HR for renal events (n = 165), compared to 
true normotension as reference, was 1.24 (95% CI 0.55–2.78) 
for white-coat hypertension, 1.11 (95% CI 0.67–1.84) for 
sustained hypertension, and 1.98 (95% CI 1.14–3.43) for 
truly resistant hypertension. 
DIAGNOSIS
In a review published in 2012 [17], we highlighted several 
diagnostic criteria that need to be fulfilled to ascertain the 
presence of treatment-resistant hypertension. Foremost, sec-
ondary hypertension should be excluded, using procedures 
that fall beyond the scope of this review but are outlined in 
current guidelines [4]. 
Blood pressure measurement 
The time has come to revise the diagnosis of resistant hy-
pertension by making ambulatory BP measurement a con-
dicio sine qua non. The United States Preventive Services 
Task Force [18], the United Kingdom National Institute for 
Health and Clinical Excellence [19], the European Society of 
Hypertension [20], and the Canadian Hypertension Educa-
tion Programme [21] carefully examined the evidence as 
to which method of BP measurement is best. All of them 
forcefully recommended ambulatory BP monitoring as the 
method of choice [18–21]. The greater number of readings, 
the absence of digit preference and observer bias, and the 
minimisation of the white-coat effect all contribute to the 
prognostic superiority of ambulatory over office BP [22, 23]. 
The major contribution of ambulatory BP monitoring to risk 
stratification is the cross-classification between office and 
ambulatory BP in untreated people [24] as well as in treated 
patients [25]. In clinical practice, the commonly used 
definition of white-coat hypertension is a raised in-office 
BP in the presence of a normal daytime ambulatory BP. 
Results of event-driven studies convincingly demonstrated 
that the risk of cardiovascular disease is lower in patients 
with white-coat hypertension than in those with raised 
ambulatory BP, even after controlling for concomitant risk 
factors [26].
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Self-measured BP at home shares some of the advantages 
of ambulatory BP, such as the greater number of readings and 
the identification of the white-coat effect [27]. However, home 
BP measurement cannot replace 24-h ambulatory monitoring 
as the gold standard to exclude pseudo-resistant hypertension. 
For instance, using home instead of ambulatory monitoring 
misses the high-risk diagnoses of masked or sustained hyper-
tension in over 25% of patients [28]. Thus, 24-h ambulatory 
monitoring is the cornerstone in diagnosing and managing 
resistant hypertension, although it might be alternated with 
self-measurement at home in optimising drug treatment [27]. 
Adherence 
As already reported 30 years ago [29] and confirmed since 
then in numerous studies [30, 31], drug adherence is a major 
problem in patients with resistant hypertension. Drugs do not 
work in patients who do not take them. Non-adherence is 
therefore a major cause of pseudo-resistance and should al-
ways be assessed in treatment-resistant hypertension. Indirect 
methods to evaluate drug adherence are vulnerable to biases 
or misclassification and amongst others include pill counts, 
interviews with patients, self-reported drug use, pharmacody-
namic signs such as heart rate on b-blockers, or reactive activa-
tion of the renin-angiotensin-aldosterone axis on treatment 
with angiotensin-converting enzyme inhibitors or blockers 
of the angiotensin I type-1 receptor. Scores of 8, 7 to 6, and 
less than 6 obtained by administering the eight-item Morisky 
Medication Adherence Scale [32] signify high, medium, and 
low adherence, respectively. Rates of prescription refills are 
readily available to obtain objective data, but require a closed 
pharmacy system and do not allow evaluating whether the 
prescribed drugs were truly taken [33]. The same applies to 
electronic medication monitors that produce quantifiable re-
sults and track patterns of taking medication [31], but require 
return visits, repackaging drugs, and expensive technology. 
Objective methods include witnessed drug intake [34] and 
measuring drugs or their metabolites in body fluids [35]. 
To our knowledge, only four trials of renal denervation 
in treatment-resistant hypertension [34, 36–38] applied 
a stringent approach to assess adherence. In the Oslo trial 
(NCT01673516) [34], 19 of 65 screened patients (29.2%) 
were excluded from randomisation because ambulatory BP 
normalised after witnessed drug intake just before the quali-
fying visit. In the Renal Denervation for Hypertension Trial 
(DENERHTN; NCT01570777) [36] drug adherence was as-
sessed at the six-month visit in 85 of 106 randomised patients 
(80.2%) by determining the urinary N-acetyl-seryl-aspartyl-ly-
syl-proline/creatinine ratio [39] and by ultra-high-performance 
liquid chromatography tandem mass spectrometry to detect 
the drugs in urine or plasma [35]. The prevalence of nonad-
herence in DENERHTN was comparable in both treatment 
groups, amounting to approximately 50%. The Renal Sympa-
thetic Denervation as a New Treatment for Therapy-Resistant 
Hypertension Trial (SYMPATHY; NCT01850901) [37] and 
the Investigator-Steered Project on Intravascular Denerva-
tion for Management of Treatment-Resistant Hypertension 
(INSPiRED; NCT01505010) [38] are the only trials of renal 
denervation in which drug adherence was assessed by 
measuring drug concentrations at baseline and follow-up. 
In 78 of 139 (56.1%) patients randomised in SYMPATHY, 
blood samples were drawn synchronously with BP measure-
ments. Neither patients nor physicians knew that adherence 
was being monitored. In 80% of patients, fewer medications 
were detected than prescribed, and adherence changed 
during follow-up in 31% of patients [37]. In the INSPiRED 
pilot trial [38], nonadherence was observed in four of nine 
(44%) patients randomised to control and in three of six (50%) 
allocated to renal denervation. Nonadherence at any time 
from baseline to the six-month visit occurred in eight (88.9%) 
patients vs. four (66.7%), respectively, randomised to control 
or renal denervation. In the SPYRAL HTN-OFF MED trial 
(NCT02439749) [40], overall compliance with the require-
ment to be off antihypertensive medications in 80 patients 
from baseline until the three-month visit was 85.5%. 
Poor adherence is not only a cause of pseudo-resistant 
hypertension but is also an indicator of poor prognosis [41, 
42]. A database maintained by 400 Italian primary care 
physicians included 18,806 newly diagnosed hypertensive 
patients, aged 35 years or more, who were initially free of 
cardiovascular disease [41]. Adherence was subdivided a priori 
into three categories: high (proportion of days covered by 
filled prescriptions ≥ 80%), intermediate (40%–79%), and 
low (< 40%) [43]. Six months after the index diagnosis, 8.1%, 
40.5%, and 51.4% of patients were classified as having high, 
intermediate, and low adherence levels, respectively. The 
composite cardiovascular endpoint consisted of first-ever 
acute coronary syndromes, angina pectoris, and cerebrovas-
cular events also including transient ischaemic attack. Over 
4.6 years of follow-up, the crude incidence of the composite 
endpoint was 7.4, 8.4, and 7.5 per 1000 patient-years, for low, 
intermediate, and high adherers, respectively. After statistical 
modelling and cumulative adjustments for confounders, the 
HR associated with high vs. low adherence was 0.62 (95% 
CI 0.40–0.96; p = 0.032) [41]. 
Patients with resistant hypertension can adhere better 
to medication with the use of educational measures and be-
havioural interventions targeted to overcome the resistance 
to treatment [2, 44]. However, more than 50% of patients 
with refractory hypertension remained non-compliant with 
medications when blood and urine levels were measured 
[37, 38, 40]. Renal denervation trials confirm that: (1) poor 
drug adherence is a frequent cause of apparently resistant 
and difficult-to-treat hypertension, (2) drug adherence is 
a dynamic phenomenon influenced by complex psycho-
social determinants and cannot be captured by any single 




potential confounder in trials assessing new treatment mo-
dalities of resistant hypertension [45]. These findings highlight 
the necessity to address adherence as described in the next 
section of our review. 
MANAGEMENT 
Renal sympathetic nerves play an important role in regulating 
BP. The efferent sympathetic nervous outflow to the kidney 
stimulates renin release, promotes sodium and water reten-
tion, and reduces renal blood flow [46]. Sympathetic nerv-
ous drive to the kidney is increased in hypertensive patients, 
particularly in resistant hypertension [47]. Other contributing 
causes of resistant hypertension include chronic kidney dis-
ease, hyperaldosteronism, and obstructive sleep apnoea [48]. 
The approach to the management of resistant hypertension, 
confirmed by ambulatory BP monitoring and assessment of 
adherence, should be comprehensive and include lifestyle 
measures and management of risk factors as reviewed else-
where [2, 44]. 
Medical treatment 
Optimising pharmacological treatment of confirmed treat-
ment-resistant hypertension rests on a few simple principles: 
(i) use of combinations of antihypertensive drugs with different 
mode of action in line with the AB/CD algorithm [49] (Fig. 1), 
which in contrast to voluminous multipage guidelines is eas-
ily understandable for physicians who are not hypertension 
specialists [49]; (ii) use of antihypertensive agents with a long 
duration of action based on their molecular structure rather 
than on their galenic formulation, the so-called “forgiving 
drugs” [50]; (iii) up-titration of each drug to the highest dose 
that does not produce side-effects; (iv) inclusion of a diuretic 
in the drug combination; (v) once the right combination has 
been found by rotation through and combining drug classes, 
stimulation of adherence by reducing the pill load through 
prescription of single-pill combination tablets including two 
or three antihypertensive agents in adjustable doses [31]; 
and (vi) attempting use of aldosterone receptor antagonists 
or b-blockers if not contraindicated. 
Consistent with the notion that resistant hypertension is 
common in patients with primary hyperaldosteronism, min-
eralocorticoid receptor antagonists provide significant benefit 
in lowering BP when added to existing multidrug regimens 
[51–53]. The strongest evidence to support the use of aldoster-
one receptor blockers originates from the recently published 
PATHWAY-2 trial (NCT 02369081). In this double-blind, 
placebo-controlled, crossover trial 335 patients were ran-
domly assigned to sequential treatment with spironolactone, 
doxazosin, bisoprolol, and placebo [54]. Eligibility criteria 
included: age ranging from 18 to 79 years, a seated clinic sys-
tolic pressure of 140 mmHg (135 mmHg in diabetic patients) 
or greater, a home systolic blood pressure (SBP; 18 readings 
over four days) of 130 mmHg or greater, and treatment for 
at least three months with the maximally tolerated doses of 
three antihypertensive agents. The average reduction in home 
SBP by spironolactone was 8.7 mmHg superior to placebo 
(95% CI 7.7–9.7 mmHg), 4.3 mmHg superior to the mean 
of the other two active treatments (doxazosin and bisoprolol; 
95% CI 3.4–5.1 mmHg), 4.0 mmHg superior compared to 
doxazosin (95% CI 3.0–5.0 mmHg), and 4.5 mmHg supe-
rior to bisoprolol (95% CI 3.5–5.5 mmHg). Spironolactone 
was the most effective blood-pressure lowering treatment 
throughout the distribution of baseline plasma renin, but its 
margin of superiority and likelihood of being the best drug 
for the individual patient were greater in the lower than 
higher ends of the plasma renin distribution. In only six of 
285 patients who received spironolactone, serum potassium 
exceeded 6.0 mmol/L on a single occasion [54], suggesting 
Figure 1. Recommendation for combining blood-pressure lowering drugs according to the AB/CD rule. Modified from [49]; 
A — angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; B — b-blockers; C — calcium-channel blockers;  
D — diuretic (thiazide/thiazide-like)
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that spironolactone can be administered without excessive 
risk of hyperkalaemia. 
Amiloride antagonises the epithelial sodium channel in 
the distal collecting duct of the kidney and functions as an 
indirect aldosterone antagonist. In a blinded comparison, ami-
loride 10 mg daily, spironolactone 25 mg daily, or a combina-
tion of both were used as add-on therapy in African-American 
patients whose BP was uncontrolled on a two-drug regimen 
consisting of a diuretic (a thiazide diuretic in 92% of patients 
and a loop diuretic in the remaining 8%) and a calcium chan-
nel blocker [53]. The mean decreases in SBP and diastolic 
blood pressure (DBP) compared with placebo were, respec-
tively, 12.2 mmHg and 4.8 mmHg for amiloride, 7.3 mmHg 
and 3.3 mmHg for spironolactone, and 14.1 mmHg and 
5.1 mmHg for the combination [53]. The most common 
adverse effect of spironolactone is breast tenderness with or 
without breast enlargement, particularly in men. If this occurs, 
amiloride is an alternative to spironolactone. 
Arterial vasodilators, such as the potassium-channel 
opener minoxidil [55] or the selective endothelin type A an-
tagonist darusentan [56], are other options to be considered 
in treatment-resistant hypertension in countries where these 
drugs are registered. However, fluid retention, oedema oc-
curring in over 25% of patients [56], focal necrosis of the 
papillary heart muscle [55] and subendocardial areas of the 
left ventricle [56], arrhythmia [55, 56], pericardial effusion 
[55], and heart failure [55, 56] limit their clinical application 
to patients in whom other treatment options failed. 
Guidelines fall short in describing how BP must be fol-
lowed up in patients with treatment-resistant hypertension. 
However, the same principles apply as for the use of ambula-
tory monitoring for the diagnosis of treatment-hypertension. 
After each optimisation step of the drug regimen, ambulatory 
monitoring may be repeated within two to three weeks to 
determine if adequate BP reduction has been achieved. If 
further adjustments in therapy are required, as may often be 
the case, then it is justifiable to repeate ambulatory monitoring 
at two-to-three-week intervals, until control is achieved. Once 
the daytime and nighttime BPs are controlled, ambulatory 
monitoring must only be repeated at three-month to six-month 
intervals. Self-measurement of BP at home can be used to 
obtain confirmatory evidence that the awake BP control is 
maintained [57]. To obtain a self-measured BP equivalent 
to the daytime ambulatory BP, six days of measurement are 
required, two readings in the morning and two in the even-
ing, after discarding the measurements from the first day. 
The average of the 24 remaining readings should be less than 
135 mmHg systolic and less than 85 mmHg diastolic [22, 23]. 
Device-based treatment 
Renal denervation
In 2009, the non-randomised proof-of-concept SYMPLICITY 
HTN-1 trial (NCT 00483808 and NCT 00664638) showed that 
percutaneous radiofrequency catheter-based renal sympathet-
ic nervous denervation was feasible, effective, and safe [58]. 
Among 45 analysed patients enrolled in this first-in-human 
open study, on treatment with 4.5 antihypertensive drugs, 
SBP/DBP at entry was 177/101 mmHg and decreased by 
27/17 mmHg 12 months after renal denervation [58]. After 
the proof-of-concept study, the open SIMPLICITY HTN-2 trial 
(NCT00888433) [59] enrolled treatment-resistant patients 
whose BP on treatment with 5.2 drugs was 178/98 mmHg. 
Office BP decreased by 32/12 mmHg in the denervation 
group and did not change in control patients. In the subse-
quent single-blind sham-controlled SYMPLICITY HTN-3 trial 
(NCT01418261) [60], the primary and secondary efficacy 
endpoints were the changes in systolic pressure at six months, 
as assessed by office and 24-h ambulatory monitoring, respec-
tively. The decreases in systolic pressure in the denervation 
(n = 364) compared with the control (n = 171) group were 
14.1 mmHg vs. 11.7 mmHg and 6.8 mmHg vs. 4.8 mmHg 
on office and ambulatory monitoring, respectively, resulting 
in baseline-adjusted intergroup differences of 2.4 mmHg 
(95% CI 2.1–6.9 mmHg; p = 0.26) and 2.0 mmHg (95% CI 
–1.0–5.0 mmHg; p = 0.98) [60]. SYMPLICTY HTN-3 [60] and 
other trials reporting similarly disappointing [37, 61–66] or 
borderline significant [67] results, even if all of them confirmed 
the safety of the procedure, shattered the prospect of bringing 
renal denervation to clinical application in treatment-resistant 
hypertension (Fig. 2). Of note, among the randomised clini-
cal trials (Fig. 2), only WAVE IV (NCT02029885) [66] applied 
externally delivered ultrasound energy to sever the renal 
nerves. All other trials [37, 38, 58–66] used an intraarterial 
approach to deliver radiofrequency energy. A randomised trial 
using intravascularly delivered ultrasound energy is ongoing 
(RADIANCE-HTN; NCT02649426) and expected to report in 
2018. A study showing the feasibility of a new endovascular 
approach to renal denervation, using chemical necrolysis via 
periadventitial infusion of dehydrated alcohol (ethanol), still 
needs to be followed up by a properly designed randomised 
clinical trial. 
One notable exception to the aforementioned disap-
pointing results was the INSPiRED pilot trial, which after the 
publication of SYMPLICITY HTN-3 received ethical clearance 
to randomise 18 patients [38]. Three Belgian hypertension 
centres screened 29 patients on treatment with three drugs 
or more, of whom 17 after optimisation of treatment were 
randomised and 15 were analysed six months later, while 
medical treatment was continued (n = 9) or combined with 
renal denervation by the EnligHTN™ multi-electrode system 
(n = 6). The baseline-adjusted systolic/diastolic differences 
amounted to 19.5/10.4 mmHg (change in control vs. interven-
tion group, +7.6/+2.2 vs. –11.9/–8.2 mmHg; p = 0.088) for 
office BP and 22.4/13.1 mmHg (+0.7/+0.3 vs. –21.7/–12.8; 
mmHg; p ≤ 0.049) for 24-h BP (Fig. 2), the primary efficacy 
endpoint. At six months electrocardiogram voltages and the 
number of prescribed drugs (p ≤ 0.036) were lower in renal 




tured by measuring drug levels in urine were similar in both 
groups [38]. 
In view of the disappointing results of renal denervation 
in patients with treatment resistant-hypertension, manu-
factures changed tactics, turned to untreated hypertensive 
patients or treated patients with mild hypertension, and 
shortened follow-up from six to three months. The SPYRAL 
HTN-OFF MED study (NCT02439749) evaluated the effect 
of renal denervation on BP in the absence of antihypertensive 
medications [40]. Eligible patients were drug-naïve (90%) or 
discontinued their antihypertensive medications for three to 
four weeks (10%) and had an SBP ranging from 150 mmHg to 
180 mmHg and from 140 mmHg to 170 mmHg on office and 
24-h ambulatory monitoring, respectively, and an office DBP 
of 90 mmHg or more. They were randomly assigned to renal 
denervation (n = 38) or sham control (n = 42). Office and 
24-h ambulatory SBP/DBP decreased significantly (p ≤ 0.003) 
from baseline to three months by 10.0/5.3 mmHg and by 
5.5/4.8 mmHg in the renal denervation and control group, 
respectively, resulting in mean baseline-adjusted differences 
of 7.7/4.9 mmHg (95% CI 1.5–14.0 mmHg/–1.4–8.5 mmHg; 
p ≤ 0.016) on office measurement and 5.0/4.4 mmHg (95% 
CI 0.2–9.9 mmHg/1.6–7.2 mmHg; p ≤ 0.041) on ambulatory 
monitoring [40]. Our take on these results is that regulatory 
authorities would not approve any antihypertensive drug if 
its blood pressure-lowering effects were of a similar order of 
magnitude as observed in the SPYRAL HTN-OFF MED study 
[40]. The investigators therefore rightfully concluded that given 
the current state of knowledge regarding renal denervation, 
one could not confidently claim or endorse catheter-based 
renal denervation beyond an investigational technology [40]. 
The SPYRAL-HTN ON-MED trial (NCT02439775) has a simi-
lar design as SPYRAL HTN OFF-MED but requires patients 
to be treated with a consistent triple drug antihypertensive 
regimen [68]. As reported very recently [68], at 6 months, 
the mean baseline-adjusted differences were 6.8/3.5 mmHg 
(1.1–12.5 mmHg/0–7.0 mmHg) for office BP and 
7.4/4.1 mmHg (2.3 12.5 mmHg/0.4–7.8 mmHg) for 24-h BP 
in favour of the renal denervation group (p ≤ 0.048).
Baroreflex activation therapy
Electrical stimulation of the carotid baroreceptors acutely 
decreased arterial BP in patients with resistant hypertension 
by sympathetic inhibition [69]. The Device-Based Therapy 
Figure 2. Change in 24-h systolic blood pressure (DSBP) in patients randomised to renal denervation (RDN) or control in eight 
studies without sham control and in five sham-controlled studies. Solid points represent the point estimate in individual studies 
and have a size proportional to the inverse of the variance. Horizontal lines and diamonds denote the 95% confidence intervals 
for individual studies and pooled estimates, respectively. P-values refer to the significance of the pooled intergroup estimate and 
Cochran’s Q test for heterogeneity. For I2, values < 25%, 25%–50%, and > 50% indicate modest, moderate, and substantial 
heterogeneity, respectively 
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in Hypertension Trial (DEBuT-HT; NCT00710190) [70] 
was a non-randomised feasibility study in 45 patients with 
stage-two office hypertension while on treatment with at 
least two antihypertensive agents. After three months and 
two years, office SBP/DBP decreased by 21/12 mmHg and 
33/22 mmHg, respectively [70]. The Rheos Pivotal Trial 
(NCT00442286) [71] was a double-blind randomised trial 
in 265 patients with resistant hypertension. All patients had 
a baroreceptor-stimulating device implanted and were sub-
sequently randomised to immediate stimulation (n = 181) 
or stimulation delayed until six months after device implan-
tation (n = 84). The primary endpoint was the change in 
the office BP at six months as measured by an automated 
oscilometric device [71]. Responders had a decrease in SBP 
of at least 10 mmHg. At six months, there were 54% and 46% 
responders in the stimulated and control group, respectively 
(p = 0.005), which did not represent a significant difference 
with the 20% superiority margin (p = 0.97). At six months 
SBP decreased by 16 mmHg vs. 9 mmHg in the stimulated 
and control group (p = 0.08), and at 12 months it was similar 
in both groups, averaging 25 mmHg. Thus, although safety 
criteria were met, the study failed to meet its primary efficacy 
endpoint [71].
With technology advancing, two other studies reported 
on the efficacy of carotid baroreceptor stimulation. The Ba-
rostim neo trial (NCT01679132) was a single-arm, open-label 
study in 30 patients with resistant hypertension [72]. The 
new carotid baroreceptor-stimulating device was designed 
to work with a single electrode implanted unilaterally, mak-
ing the surgical procedure much simpler. Office SBP/DBP 
reduction was 26/12 mmHg at six months [72]. A subse-
quent single-arm study [73] reported a decrease (p < 0.01) 
in the 24-h BP six months after device implantation, from 
148 mmHg to 140 mmHg systolic and from 82 mmHg to 
77 mmHg diastolic. A recent publication [74] combined data 
from the DEBuT-HT (n = 45) [70], the US Rheos Feasibility 
trial (NCT01077180; n = 16) [75], and the Rheos Pivotal Trial 
(n = 322) [71]. Altogether, 383 patients were available for 
analysis; 143 of these had completed five years of follow-up, 
and 48 patients had completed six years of follow-up. In the 
entire cohort, office BP fell (p < 0.001) from 179 mmHg 
to 144 mmHg systolic, and from 103 mmHg to 85 mmHg 
diastolic [74]. In 25% of patients, the median number of 
medications decreased from six to three [74]. Overall, the 
evidence supporting carotid baroreceptor stimulation as 
a treatment modality in resistant hypertension remains un-
convincingly weak. The most important limitations are the 
single-arm unblinded design of most studies [70, 72, 73, 75, 
76] with the exception of the first six months of follow-up 
in the Rheos Pivotal Trial [71], failure to meet the primary 
efficacy endpoint in the Rheos Pivotal Trial [71], variable 
follow-up duration, use of office rather than 24-h ambula-
tory monitoring [70–72, 74–76], the lack of reliable data 
on adherence, and the possible influence of the nocebo 
(Hawthorne) effect [77]. 
Arteriovenous anastomosis
The novel arteriovenous ROX Coupler (ROX Medical, San 
Clemente, CA, USA) reduces BP by adding a low-resistance 
high-compliance venous segment to the central arterial tree 
[78]. An open-label randomised trial assessed the efficacy of 
this approach in patients with uncontrolled hypertension [79]. 
Eligible patients had a baseline office SBP of 140 mmHg or 
higher and an average daytime ambulatory BP of 135 mmHg 
systolic and 85 mmHg diastolic or higher, despite antihy-
pertensive treatment. The primary endpoint was the mean 
change from baseline in office and 24-h ambulatory SBPs at six 
months [79]. Mean office SBP decreased by 26.9 mmHg from 
175 mmHg in the arteriovenous coupler group (n = 44) and 
by 3.7 mmHg from 171 mmHg (n = 39) in the control group. 
Mean 24-h SBP declined by 13.5 mmHg from 157 mmHg in 
the intervention group and by 0.5 mmHg from 156 mmHg 
in controls [79]. The baseline-adjusted intergroup differ-
ences were significant (p < 0.001). Replication of this small 
trial remains necessary. Another major limitation is that the 
technique is associated with the development of symptomatic 
venous stenosis. Although this complication can be managed 
with conventional strategies, the long-term safety remains 
a matter of major concern. 
PERSPECTIVES FOR THE FUTURE 
From our review of the literature, two points emerged as 
possible new avenues for future research. 
Design of future trials 
Our review revealed that poor insight in the pathophysiologi-
cal mechanism raising BP and weak design features explain 
why most trials of devices to treat resistant hypertension 
failed to reach their efficacy endpoints. Renal denervation 
is certainly based on sound evidence on the role of the 
sympathetic nervous system [80, 81] and the kidneys [82] in 
hypertension and represents a major leap forward compared 
with the unselective sympatholytic surgery as practiced from 
the 1930s until the 1980s [83]. However, assuming that renal 
denervation would be efficacious in a large number of patients 
with a variety of conditions was overly optimistic. In rats, trans-
plantation of a kidney from a hypertensive to a normotensive 
animal produces hypertension, although by definition the 
transplanted kidney is not innervated [82]. Moreover, essen-
tial hypertension is characterised by generalised membrane 
abnormalities, which could affect the function of the vascu-
lature and many organs in various ways [84]. Isolated systolic 
hypertension in seniors is caused by stiffening of the large 
arteries and not by an increased sympathetic tone [85]. These 
concepts underline that selection of patients with essential 




exclusion of pseudo-resistance by ambulatory BP monitoring 
and checking of adherence to an optimised drug regimen, 
but also an assessment of the extent to which hypertension is 
dependent on volume overloading and sodium retention as 
opposed to increased peripheral arterial resistance, the hall-
mark of increased sympathetic tone. Non-invasive estimation 
of systemic arterial resistance requires measurement of cardiac 
index and mean arterial pressure. Furthermore, one cannot 
expect that treatment-resistant patients with severe target 
organ damage will be responsive to renal denervation. The 
European Network Coordinating Research on Renal Denerva-
tion (ENCOReD) demonstrated that worse renal function at 
baseline was associated with a lower probability of improve-
ment in the 24-h BP (odds ratio [OR] for 20-μmol/L increase 
in serum creatinine, 0.60; p = 0.05) and higher probability 
of experiencing no BP decrease (OR 1.66; p = 0.01) [86].
Patients with accessory arteries that cannot be engaged 
for renal denervation should not be enrolled in trials [87], 
although they might still benefit from the procedure. The 
BP and heart rate responses to renal nerve stimulation might 
provide a procedural endpoint indicating effective renal den-
ervation and might identify the anatomical localisation within 
the renal arterial system to be preferentially denervated [88]. 
We hope that rolling renal denervation out to untreated pa-
tients or treated patients with mild hypertension will not stop 
manufacturers from supporting clinical trials in highly selected 
patients with truly resistant hypertension, in whom all other 
treatment options failed, but who represent a much smaller 
number of clients and therefore a less profitable market.
Biomarkers 
Another hopeful development that has been shaping up over 
the past decade is the introduction in clinical practice of cir-
culating, urinary metabolic, or proteomic biomarkers, which 
provide insight in the pathophysiology of hypertension and 
which are associated with early target organ damage at a time 
when prevention remains possible, long before irreversible 
organ failure sets in. Circulating desphospho-uncarboxylated 
matrix Gla protein (dp-ucMGP) is a marker of vitamin K status 
[89]. Active MGP is a strong local inhibitor of vascular cal-
cifications [89] and helps maintain the integrity of the renal 
microcirculation [90, 91]. Mucin-1 is a high-molecular-weight 
(400 kDa), heavily O-glycosylated, type-I membrane-tethered 
glycoprotein [92]. Normal kidneys express mucin-1 in the 
thick segment of Henle’s loop and in the distal tubules and 
collecting ducts [92]. The main function of mucin-1 is to 
shield cell surfaces by maintenance of a luminal epithelial 
mucobarrier [92]. The N-terminal a-subunit of mucin-1 is 
shed when renal function starts to decline. Both circulating 
dp-ucMGP [91] and urinary mucin-1 [93] might be tested in 
treatment-resistant hypertension for the early detection of 
patients at the greatest risk of irreversible kidney damage. 
The same applies to CKD273, a multidimensional urinary 
classifier consisting of 273 peptide fragments. The American 
Food and Drug Administration recently encouraged further 
studies of CKD273 as a tool for diagnosis and risk prediction 
in chronic kidney disease [94]. CKD273 not only predicts 
deterioration of renal dysfunction [95], and earlier than 
micro-albuminuria does [96], but it is also a forerunner of 
adverse cardiovascular complications [95]. HF1 and HF2 are 
urinary proteomic classifiers, respectively consisting of 85 and 
671 peptides, predictive of imminent diastolic left ventricular 
dysfunction and the incidence of cardiovascular complications 
[97, 98]. A recent study suggests that urinary markers of the 
citric acid metabolism might predict the treatment response 
to spironolactone in patients with treatment-resistant hyper-
tension [99]. Our view on the future is that the use of these 
omics technologies, after proper validation in randomised 
clinical trials [100], will revolutionise selection of patients 
with resistant hypertension for the treatment options which 
are already currently available or are becoming part of the 
clinical armamentarium in the future, thereby giving these 
patents access to a personalised approach. 
CONCLUSIONS
Once the diagnosis of resistant hypertension is confirmed, 
optimisation of drug treatment remains the cornerstone of its 
management. For now, device treatment should remain the 
ultima ratio in adherent and truly resistant patients with severe 
hypertension, in whom all other efforts to reduce BP have failed. 
The intervention should only be offered to patients within 
a context of clinical research in highly skilled tertiary referral 
centres. Future research should focus on a better understanding 
of the intrinsic (in the patients) and extrinsic (e.g. environmental 
stressors) mechanisms that contribute to an adherent patient’s 
irresponsiveness to blood pressure-lowering drugs. Biomark-
ers predictive of target organ damage and new technologies, 
such as renal nerve stimulation, might help in selecting the few 
patients who might benefit from device therapy. 
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